Lebogang G. Julius

Lebogang G. Julius

Auto-generated profile, based on publicly available information

Lebogang G. Julius

Faculty of Science, Department of Chemistry University of Botswana Gaborone Botswana

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Bioinorganic Chemistry and Applications
Verified
Journal Article
Open access
PDF file
JMJames T.P. Matshwele
James T.P. Matshwele
SOSebusi Odisitse
Sebusi Odisitse
DMDaphne Mapolelo
Daphne Mapolelo
MLMelvin Leteane
Melvin Leteane
LJLebogang G. Julius
Lebogang G. Julius
FNFlorence Nareetsile
Florence Nareetsile
A new hexadentate 2-picolyl-polypyridyl-based ligand (4, 4'-(butane-1, 4-diylbis(oxy))bis(N, N-bis(pyridin-2-ylmethyl)aniline)) (2BUT) (1) and its corresponding Ru(II/III) complexes were synthesized and characterized, followed by assessment of their possible bioactive properties towards drug-resistant and non-drug-resistant bacteria. Spectroscopic characterization of the ligand was done using proton NMR, FTIR, and ESI-MS, which showed that the ligand was successfully synthesized. The Ru(II/III) complexes were characterized by FTIR, UV/Vis, elemental analysis, proton NMR, ESI-MS, and magnetic susceptibility studies. The analysis of ESI-MS data of the complexes showed that they were successfully synthesized. Empirical formulae derived from elemental analysis of the complexes also indicated successful synthesis and relative purity of the complexes. The important functional groups of the ligands could be observed after complexation using FTIR. Magnetic susceptibility data and electronic spectra indicated that both complexes adopt a low spin configuration. The disc diffusion assay was used to test the compounds for antibiotic activity on two bacteria species and their drug-resistant counterparts. The compounds displayed antibiotic activity towards the two non-drug-resistant bacteria. As for the drug-resistant organisms, only [Ru2(2BUT)(DMF)2(DPA)2](BH4)43 and 2, 2-dipyridylamine inhibited the growth of MRSA. Gel electrophoresis DNA cleavage studies showed that the ligands had no DNA cleaving properties while all the complexes denatured the bacterial DNA. Therefore, the complexes may have DNA nuclease activity towards the bacterial genomic material.

27 December 2023 in Applied Organometallic Chemistry
Verified
Journal Article
Open access
LJLebogang G. Julius
Lebogang G. Julius
DMDaphne T. Mapolelo
Daphne T. Mapolelo
TDTaye B. Demissie
Taye B. Demissie
FNFlorence Nareetsile
Florence Nareetsile
Moses KoobotseMoses Koobotse
Moses Koobotse
JMJames T.P. Matshwele
James T.P. Matshwele
A new polypyridyl ligand 4‐(4‐nitrophenoxy)‐N,N‐bis (pyridin‐2‐ylmethyl)aniline (L1) and its three ruthenium (II/III) complexes, [Ru (Cl)3L1] (C1), [Ru(L1)2]Cl (C2), and [RuCl (dpa)L1] (C3) where dpa = 2,2‐dipyridylamine, have been successfully synthesized and characterized using Fourier‐transform infrared spectroscopy (FTIR), elemental analysis, proton nuclear magnetic resonance (1H NMR), high‐resolution electrospray ionization mass spectrometry (HR‐ESI‐MS), thermal analysis (thermogravimetric analysis [TGA] and differential scanning calorimetry [DSC]), UV/Vis absorption, and magnetic susceptibility. The structures of the ligand and the complexes were optimized, and the structural characteristics were determined by density functional theory (DFT) using the B3LYP‐GD3/6‐311G++(d,p) method. Optimized FTIR vibrational frequencies and 1H NMR chemical shifts agreed well with the corresponding experimental FTIR and 1H NMR data. In vitro cytotoxicity of the ligand and the complexes were evaluated against the MCF‐7 breast cancer cell line. Ligand L1 was the most potent with an IC50 of 38.45 μM, followed by C2 with an IC50 of 45.23 μM. However, the ligand and the complexes showed low antiproliferative activity compared to cisplatin, which had an IC50 of 9.67 μM. To predict the reactivity trend of L1 and the complexes, frontier molecular orbital (FMO) analysis was performed. The FMO energy gap (Eg = ELUMO − EHOMO) for C2 was found to be 1.675 eV, which was the lowest among all the complexes or L1. In addition, molecular docking studies were carried out so as to predict the binding capacity of L1 and the complexes to estrogen receptor alpha (ER‐α). The results showed that C2 has the most negative binding energy score (−9.63 kcal/mol), which indicates more stable adducts with the key amino acid residues at the active sites of ER‐α. Furthermore, C2 displayed the lowest inhibition constant (Ki) of 0.09 μM compared to all the complexes or L1. These results are very promising and show that the novel complex C2 may help in the development of anticancer drugs.

1 December 2022 in Crystallography Reports
Verified
Journal Article
Closed access
PDF file
JMJames T.P. Matshwele
James T.P. Matshwele
SOSebusi Odisitse
Sebusi Odisitse
OMOfentse Mazimba
Ofentse Mazimba
LJLebogang G. Julius
Lebogang G. Julius
TMThuto Mogatwe
Thuto Mogatwe
FNFlorence Nareetsile
Florence Nareetsile
The structure of pyridin-4-ylmethyl 4-aminobenzoate was determined using single crystal X-ray diffraction. The compound was also characterized by elemental analysis, which showed the product was pure, and Fourier-transform infrared spectroscopy, which showed all important functional groups associated with the molecule. The compound crystallized in the orthorhombic space group Pna21, and the unit cell parameters were: a = 11.1735(16) Å, b = 8.3548(13) Å, c = 12.3831(17) Å, V = 1156.0(3) Å3, Z = 4. The crystal structure was solved by intrinsic phasing and refined to the final values R1 = 0.0429 and wR2 = 0.1312.